Triptorelin
Trelstar, Triptodur (triptorelin) is a protein pharmaceutical. Triptorelin was first approved as Trelstar on 2000-06-15. It is used to treat prostatic neoplasms in the USA. It is known to target gonadotropin-releasing hormone receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| urogenital diseases | D000091642 |
Trade Name
FDA
EMA
Trelstar, Triptodur
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Triptorelin pamoate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TRIPTODUR KIT | Azurity | N-208956 RX | 2017-06-29 | 1 products, RLD, RS |
| TRELSTAR | Verity Pharmaceuticals | N-020715 RX | 2000-06-15 | 1 products, RLD, RS |
| TRELSTAR | Verity Pharmaceuticals | N-021288 RX | 2001-06-29 | 1 products, RLD, RS |
| TRELSTAR | Verity Pharmaceuticals | N-022437 RX | 2010-03-10 | 1 products, RLD, RS |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| prostatic neoplasms | — | D011471 | C61 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
TRIPTORELIN PAMOATE, TRIPTODUR KIT, AZURITY | |||
| 2024-06-29 | ODE-149 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Triptorelin Pamoate, Trelstar, Verity | |||
| 10166181 | 2029-06-30 | DP | |
Clinical
Clinical Trials
295 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infertility | D007246 | EFO_0000545 | — | 1 | 9 | 12 | 30 | 33 | 83 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | 32 | 33 | 6 | 10 | 78 |
| Female infertility | D007247 | EFO_0008560 | N97 | 2 | 6 | 4 | 4 | 12 | 24 |
| Endometriosis | D004715 | EFO_0001065 | N80 | 1 | 2 | 5 | 3 | 5 | 14 |
| Fertilization in vitro | D005307 | — | — | — | — | 2 | 7 | 4 | 13 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 1 | 1 | 1 | 4 | 5 | 11 |
| Ovarian hyperstimulation syndrome | D016471 | — | — | — | 1 | 1 | 3 | 5 | 10 |
| Precocious puberty | D011629 | — | E22.8 | — | — | 7 | 2 | — | 9 |
| Intracytoplasmic sperm injections | D020554 | — | — | — | — | — | 4 | 1 | 5 |
| Assisted reproductive techniques | D027724 | — | — | — | — | — | 1 | 3 | 4 |
Show 11 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 10 | 7 | — | 7 | 26 |
| Adenocarcinoma | D000230 | — | — | — | 3 | 3 | — | 1 | 7 |
| Adenomyosis | D062788 | EFO_1001757 | N80.0 | 1 | 1 | 2 | — | 2 | 5 |
| Neoplasms | D009369 | — | C80 | — | 2 | 3 | — | 2 | 5 |
| Recurrence | D012008 | — | — | — | 2 | 2 | — | 1 | 5 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | — | 4 | 1 | — | — | 4 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 2 | 1 | — | 1 | 3 |
| Male breast neoplasms | D018567 | — | — | 1 | 1 | 1 | — | 1 | 3 |
| Fertility preservation | D059247 | — | — | — | 1 | 1 | — | 2 | 3 |
| Lymphoma | D008223 | — | C85.9 | — | 2 | 3 | — | — | 3 |
Show 9 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Triple negative breast neoplasms | D064726 | — | — | — | 3 | — | — | — | 3 |
| Helping behavior | D006379 | — | — | 1 | 1 | — | — | 1 | 2 |
| Leiomyoma | D007889 | — | D25 | 1 | 1 | — | — | 1 | 2 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | 1 | — | — | 1 | 2 |
| Infections | D007239 | EFO_0000544 | — | 1 | 1 | — | — | — | 1 |
| Ectopic pregnancy | D011271 | — | O00 | 1 | 1 | — | — | — | 1 |
| Salpingitis | D012488 | — | N70.91 | 1 | 1 | — | — | — | 1 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | 1 | — | — | — | 1 |
| Salivary gland neoplasms | D012468 | EFO_0003826 | D11 | — | 1 | — | — | — | 1 |
| Female urogenital diseases | D052776 | — | — | — | 1 | — | — | — | 1 |
Show 6 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ovulation induction | D010062 | — | — | — | — | — | — | 4 | 4 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 3 | 3 |
| Ovarian pregnancy | D065172 | — | O00.2 | — | — | — | — | 1 | 1 |
| Embryo implantation | D010064 | — | — | — | — | — | — | 1 | 1 |
| Female genital diseases | D005831 | EFO_0009549 | N85 | — | — | — | — | 1 | 1 |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | — | — | — | 1 | 1 |
| Luteolysis | D003341 | — | — | — | — | — | — | 1 | 1 |
| Myofibroma | D047708 | — | — | — | — | — | — | 1 | 1 |
| Hodgkin disease | D006689 | — | C81 | — | — | — | — | 1 | 1 |
| Pregnancy rate | D018873 | — | — | — | — | — | — | 1 | 1 |
Show 9 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Triptorelin |
| INN | triptorelin |
| Description | Triptorelin is an oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-tryptophyl, leucyl, arginyl, prolyl and glycinamide residues joined in sequence. It is an agonist analogue of gonadotropin-releasing hormone. It has a role as a gonadotropin releasing hormone agonist, an antineoplastic agent and a contraceptive drug. |
| Classification | Peptide |
| Drug class | prehormones or hormone-release stimulating peptides |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O |
Identifiers
| PDB | — |
| CAS-ID | 57773-63-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201334 |
| ChEBI ID | 63633 |
| PubChem CID | 25074470 |
| DrugBank | DB06825 |
| UNII ID | 9081Y98W2V (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
GNRHR
GNRHR
Organism
Homo sapiens
Gene name
GNRHR
Gene synonyms
GRHR
NCBI Gene ID
Protein name
gonadotropin-releasing hormone receptor
Protein synonyms
gnRH receptor, gnRH-R, gonadotropin-releasing hormone (type 1) receptor 1, leutinizing hormone releasing horomone receptor, leutinizing-releasing hormone receptor, luliberin receptor, type I GnRH receptor
Uniprot ID
Mouse ortholog
Gnrhr (14715)
gonadotropin-releasing hormone receptor (Q61611)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,450 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,602 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use